Clinical trials: Sacubitril/Valsartan
Heart Failure
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
The purpose of this study was to evaluate long-term safety and tolerability and to provide post-trial access to sacubitril/valsartan to eligible participants who successfully completed CLCZ696B2319 (PANORAMA-HF) core study Part 2…
- Trial name
- NCT03785405
- Testing
- sacubitril/valsartan
- Where
- 79 sites in United States, Argentina and 25 more
- Volunteers
- 216 people
- Sponsor
- Novartis Pharmaceuticals
Left Ventricular Diastolic Function
Impact of Sacubitril/Valsartan on LV Diastolic Function in HFrEF
This prospective cohort study evaluates the effects of six months of sacubitril/valsartan (ARNI) therapy on left ventricular diastolic function in patients with heart failure with reduced ejection fraction (HFrEF) using…
- Trial name
- NCT07157527
- Volunteers
- 70 people
- Sponsor
- Assiut University
Hypotension, Heart Failure
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
The DAPA-HF trial demonstrated that dapagliflozin was able to reduce the risk of worsening heart failure events and cardiovascular death comparing to placebo in patients with reduced ejection fraction further to standard of care.
- Trial name
- NCT04575675
- Testing
- Dapagliflozin, Sacubitril-Valsartan, Beta blocker
- Where
- Taiwan
- Volunteers
- 78 people
- Sponsor
- Cheng-Hsin General Hospital
Heart Failure With Reduced Ejection Fraction
The ENVI Study: Effect of Entresto on Left Ventricular Remodelling on Cardiac MRI
A prospective, single centre, observational cohort study at University Hospital Southampton NHS Foundation Trust of 50 consecutive patients with Heart Failure with reduced Ejection Fraction and Ejection Fraction ≤35% who are…
- Trial name
- ENVI (NCT05348226)
- Testing
- Additional Cardiac Magnetic Resonance Scan
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Chronic Heart Failure
Special Drug Use Surveillance for Entresto Tablets
This is a single arm, multicenter, observational study in Japanese chronic heart failure patients.
- Trial name
- NCT04781881
- Testing
- Entresto
- Where
- 121 sites in Japan
- Volunteers
- 688 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Systolic
Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin
The study measure multiple neurohormones in patients with heart failure being treated with Sacubitril/Valsartan in increasing doses over an 8 week period.
- Trial name
- NCT03553303
- Testing
- Sacubitril / Valsartan Oral Tablet
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Heart Failure
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
The purpose of this open-label study was to collect additional safety information of sacubitril/valsartan and to provide post-trial access to sacubitril/valsartan for the eligible Japanese patients who completed…
- Trial name
- NCT06149104
- Testing
- sacubitril/valsartan
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
ARNI, Pediatric Dilated Cardiomyopathy
Comparative Efficacy of ARNI Versus ACE Inhibitor Therapy in Egyptian Children With Dilated Cardiomyopathy
This is a prospective, cohort study designed to evaluate the efficacy and safety of sacubitril/valsartan versus captopril in children with dilated cardiomyopathy (DCM) admitted to Assiut University Children Hospital over a…
- Conditions
- ARNI, Pediatric Dilated Cardiomyopathy, ACE Inhibitor
- Trial name
- NCT07197372
- Volunteers
- 70 people
- Sponsor
- Assiut University